ADC Therapeutics (ADCT) Non Operating Income (2023 - 2026)

ADC Therapeutics' (ADCT) quarterly Non Operating Income came in at -$7.7 million in Q1 2026, down 3904.43% year-on-year from $203000.0 in Q1 2025, and down 934.92% quarter-over-quarter from $925000.0 in Q3 2025.

ADC Therapeutics (ADCT) Non Operating Income (2023 - 2026) Analysis & Trends

ADC Therapeutics has disclosed Non Operating Income across 4 years of filings, most recently posting -$7.7 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - 5.75 Mn
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - 444,000.00
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn -
9 Abivax 91.71 Bn 91.71 Bn - 9.35 Mn
10 ADC Therapeutics 167.24 Mn -63.76 Mn 7.33 Mn -7.72 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -7.72 Mn
Sep 30, 2025 925,000.00
Jun 30, 2025 -182,000.00
Mar 31, 2025 203,000.00
Sep 30, 2024 1.62 Mn
Jun 30, 2024 2.75 Mn
Mar 31, 2024 -12.14 Mn
Sep 30, 2023 860,000.00
Jun 30, 2023 -13.00 Mn